期刊文献+

免疫组化在肺小活检中对肺癌组织学分型的鉴别诊断意义 被引量:13

The differential diagnosis value of immunohistochemistry in lung biopsy
下载PDF
导出
摘要 目的:探讨应用免疫组织化学标记在肺小活检中提高肺癌组织学分型的鉴别诊断意义。方法:收集三家医院小活检肺癌128例,免疫组化根据形态学观察情况选用抗体包括p63、p40、CK5/6、TTF-1、NapsinA、CK7、CgA、Syn、CD56、Ki-67等标记,通过单纯形态学观察和结合免疫组化分别进行肺癌组织学分型。结果:128例肺癌中单凭形态学观察肺癌分型准确率为77.34%,结合免疫组化分型准确率为91.41%,提高了14.07%。结论:肺癌小活检标本行免疫组化检测能提高肺癌组织学分型。建议在形态学基础上综合运用一组抗体:鉴别腺癌与鳞癌时选用TTF-1、NapsinA、CK7、p40、p63、CK5/6;倾向小细胞癌时选用CgA、Syn、CD56、Ki-67、TTF-1、p40。 Objective: To investigate the differential diagnostic value of immunohistochemical markers in lung biopsy to improve the histological type of lung cancer. Methods: A total of 128 patients with small lung cancer were collected from three hospitals,according to the morphological observation,immunohistochemical staining was performed with antibodies and reagents including p63,p40,CK5/6,TTF-1,NapsinA,CK7,CgA,Syn,CD56,Ki-67 and so on.The histological type of lung cancer was observed by morphological observation and morphological observation combined with immunohistochemistry respectively. Results: In 128 cases,the accuracy rate of lung cancer classification was only 77.34%,The accuracy of typing was 91.41% in combination with immunohistochemistry,which increased 14.07%. Conclusion: Immunohistochemical staining of lung cancer with small biopsy specimens improves the histological classification of lung cancer.We propose to use a set of antibodies based on morphology,differentiation of adenocarcinoma and squamous cell carcinoma using TTF-1,NapsinA,CK7,p40,p63,CK5/6.Consider small cell carcinoma using CgA,Syn,CD56,Ki-67,TTF-1,p40.
作者 赵声春 贾其磊 章培 徐德 Zhao Shengchun;Jia Qilei;Zhang Pei;Xu De(Department of Pathology;Department of Surgery,Qingbaijiang People's Hospital,Sichuan Chengdu 610300,China;Department of Pathology,the Second People's Hospital of Chengdu,Sichuan Chengdu 610017,China;Department of Pathology,Affiliated Hospital of Panzhihua University,Sichuan Panzhihua 617000,China.)
出处 《现代肿瘤医学》 CAS 2018年第12期1848-1851,共4页 Journal of Modern Oncology
关键词 免疫组化 小活检 肺癌 immunohistochemistry small biopsy lung cancer
  • 相关文献

参考文献4

二级参考文献34

  • 1Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015 [J]. CA.. a cancer journal for clinicians, 2015, 65(1):5-29.
  • 2Seagliotti G, Hanna N, Fossella F, et al. The differential effi- cacy of pemetrexed according to NSCLC histology., a review of two Phase III studies[J]. The oncologist, 2009, 14 (3) : 253- 263.
  • 3Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance peme- trexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study[J]. Lancet, 2009, 374(9699) :1432-1440.
  • 4Sandler A, Gray R, Perry MC, et al. Paelitaxebearboplatin a- lone or with bevacizumab for non-small-cell lung cancer[J]. The New England journal of medicine, 2006, 355(24) ~2542-2550.
  • 5E1-Bayoumi E, Silvestri GA. Bronchoscopy for the diagnosis and staging of lung cancer[J]. Seminars in respiratory and critical care medicine, 2008, 29(3) ,261-270.
  • 6Herth FJ, Eberhardt R, Ernst A. The future of bronchoscopy in diagnosing, staging and treatment of lung cancer[J]. Respira- tion: international review of thoracic diseases, 2006, 73 (4) : 399-409.
  • 7Ettinger DS, Wood DE, Akerley W, et al. Non-small cell lung cancer, version 1. 2015[J]. Journal of the National Comprehen- sive Cancer Network: JNCCN, 2014, 12(12) :1738-1761.
  • 8Mok TS, Zhou Q, Leung L, et al. Personalized medicine for non-small-cell lung cancer[J]. Expert review of anticancer ther- apy, 2010, 10(10)~1601-1611.
  • 9Domingo G, Perez CA, Velez M, etal. Santos ES~ EGF recep- tor in lung cancer: a successful story of targeted therapy[J]. Expert review of anticancer therapy, 2010, 10(10) : 1577-1587.
  • 10Villaflor VM, Salgia R. Targeted agents in non-small cell lung cancer therapy: What is there on the horizon[J]. Journal of car- cinogenesis, 2013, 12:7.

共引文献133

同被引文献89

引证文献13

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部